Five-Year OS Data for Dabrafenib/Trametinib Combo in Melanoma

Georgina V. Long, BSc, PhD, MBBS,&nbsp;professor of medical melanoma oncology, Melanoma Institute Australia, discusses 5-year overall survival data from a phase II trial of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with <em>BRAF V600</em>-mutant unresectable or metastatic melanoma during the 2017 ASCO Annual Meeting.